20,033 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Acquired by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 20,033 shares of the specialty pharmaceutical company’s stock, valued at approximately $625,000.

Several other hedge funds have also added to or reduced their stakes in SUPN. SG Americas Securities LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth about $129,000. Russell Investments Group Ltd. lifted its position in Supernus Pharmaceuticals by 205.2% during the first quarter. Russell Investments Group Ltd. now owns 97,988 shares of the specialty pharmaceutical company’s stock worth $3,342,000 after acquiring an additional 65,880 shares during the last quarter. ProShare Advisors LLC grew its position in shares of Supernus Pharmaceuticals by 8.0% in the first quarter. ProShare Advisors LLC now owns 13,859 shares of the specialty pharmaceutical company’s stock valued at $473,000 after purchasing an additional 1,021 shares during the last quarter. State Board of Administration of Florida Retirement System increased its stake in shares of Supernus Pharmaceuticals by 250.6% during the first quarter. State Board of Administration of Florida Retirement System now owns 49,160 shares of the specialty pharmaceutical company’s stock worth $1,781,000 after purchasing an additional 35,137 shares during the period. Finally, Covestor Ltd lifted its holdings in Supernus Pharmaceuticals by 15.3% during the 1st quarter. Covestor Ltd now owns 2,702 shares of the specialty pharmaceutical company’s stock worth $92,000 after purchasing an additional 358 shares during the last quarter.

Insider Transactions at Supernus Pharmaceuticals

In other news, CEO Jack A. Khattar sold 125,000 shares of the business’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the completion of the transaction, the chief executive officer now owns 926,172 shares of the company’s stock, valued at approximately $33,971,988.96. The trade was a 11.89 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Frank Mottola sold 15,000 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $36.98, for a total value of $554,700.00. Following the completion of the sale, the senior vice president now directly owns 8,200 shares in the company, valued at $303,236. This trade represents a 64.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 154,213 shares of company stock valued at $5,660,180. Company insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN opened at $35.57 on Friday. The business has a fifty day moving average price of $33.35 and a two-hundred day moving average price of $30.92. The stock has a market capitalization of $1.96 billion, a PE ratio of 33.24 and a beta of 0.86. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. During the same quarter in the previous year, the firm earned ($0.29) earnings per share. Supernus Pharmaceuticals’s revenue for the quarter was up 14.2% compared to the same quarter last year. On average, equities analysts expect that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Analyst Ratings Changes

SUPN has been the topic of a number of research reports. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.